Illumina Reports Q2 2026 Revenue Growth to $1.159 Billion, Net Income Declines

Illumina, Inc. reported its financial results for the second quarter of 2026, revealing total revenue of $1.159 billion, a 9.4% increase from $1.059 billion in the same quarter of the previous year. The company's product revenue rose to $982 million, up from $912 million, while service and other revenue also increased to $177 million from $147 million. Despite the revenue growth, net income for the quarter decreased to $207 million, compared to $235 million in Q2 2025, resulting in diluted earnings per share of $1.35, down from $1.49 a year earlier.

In terms of operational changes, Illumina completed the acquisition of SomaLogic on January 30, 2026, for a total purchase price of $460 million. This acquisition is expected to enhance Illumina's capabilities in the proteomics market and support its multiomics strategy. The financial results of SomaLogic have been included in Illumina's consolidated financial statements since the acquisition date. The company also reported a significant increase in goodwill, which rose to $1.284 billion from $1.113 billion, primarily due to the SomaLogic acquisition.

Geographically, revenue from the United States and Canada reached $653 million, up from $569 million, while revenue from Europe, the Middle East, Africa, and Latin America increased to $368 million from $355 million. However, revenue from Greater China declined to $56 million from $63 million, and revenue from the Asia-Pacific region rose to $82 million from $72 million. The company noted that it has implemented a new global commercial structure to improve operational efficiencies and align better with local markets.

Illumina's total assets as of June 28, 2026, were reported at $6.650 billion, slightly up from $6.644 billion at the end of the previous fiscal year. The company’s cash and cash equivalents decreased to $1.040 billion from $1.418 billion, while total liabilities remained relatively stable at $3.812 billion. The company’s employee headcount was not disclosed in the filing, but it continues to focus on cost reduction initiatives to align with its strategic goals.

Looking ahead, Illumina anticipates continued growth driven by its product innovations and market expansion efforts. The company is also closely monitoring external factors such as government funding for the National Institutes of Health and potential tariffs that could impact its operations. Illumina's management remains optimistic about the integration of SomaLogic and the potential benefits it will bring to the company's portfolio and market position.